IP Library Granted Patent US 11,220,701
Granted Patent B2
US 11,220,701 · App. 16/652,312 · Granted Jan 11, 2022

Method for enzymatic preparation of R-3 aminobutyric acid

Inventors: Chuanmin Sun (Shanghai, CN); Zhanbing Cheng (Shanghai, CN); Jianghua Jiao (Shanghai, CN); Shaonan Ding (Shanghai, CN); Zhenhua Tian (Shanghai, CN)
Assignee: ABIOCHEM BIOTECHNOLOGY CO., LTD.
C12P13/04C12N9/88C12Y403/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,220,701
App. No.
16/652,312
Granted
Jan 11, 2022
Kind
B2
Abstract

An R-3-aminobutyric acid preparation method with high efficiency and high stereoselectivity. The method comprises using aspartase with stereoisomerization catalytic activity derived from Escherichia coli to efficiently convert butenoic acid into R-3-aminobutyric acid. After only 24 h of reaction, the conversion rate is as high as ≥98%, and the ee value is ≥99.9%. The conversion efficiency is greatly improved, the reaction time is shortened, and the production costs are reduced. The method features a high yield, a high conversion rate, low costs, a short production cycle, a simple process, ease of enlargement, suitability for mass production and the like.

Claims (14)

1. A method for producing an R-3-aminobutyric acid comprising the steps of:

(1) using butenoic acid as a substrate and carrying out a stereoisomeric catalytic reaction shown in equation I to form the R-3-aminobutyric acid under the catalysis of an aspartase in a reaction system;

(b) optionally, isolating the R-3-aminobutyric acid from the reaction system after the reaction of the step (1);

wherein, the aspartase is obtained from E. coli , and

the aspartase is a mutant having 90% sequence identity to the amino acid sequence of SEQ ID NO: 5 which has two to four amino acid mutations in the amino acid sequence corresponding to the wild type aspartase shown in SEQ ID NO: 5, wherein the amino acid mutation is selected from the group consisting of threonine (T) at position 204, methionine (M) at position 338, Lysine (K) at position 341, asparagine (N) at position 343, or a combination thereof.

2. The method of claim 1 , wherein the ee value of the R-3-aminobutyric acid is ≥99.5%, and/or the conversion rate of the reaction is ≥90%.

3. The method of claim 1 , wherein the mutation in the mutant is selected from the group consisting of T204C, M338I, K341M, N343C, or a combination thereof.

4. A method for producing an R-3-aminobutyric acid comprising the steps of:

1) culturing a production strain under production conditions to obtain an R-3-aminobutyric acid;

2) optionally, isolating the R-3-aminobutyric acid from the culture system of 1),

wherein the production strain is an R-3-aminobutyric acid production strain expressing a polypeptide, and the polypeptide is an exogenous aspartase obtained from E. coli and is used to catalyze the stereoisomeric catalytic reaction as below:

wherein the exogenous aspartase is a mutant having 90% sequence identity to the amino acid sequence of SEQ ID NO: 5 which has two to four amino acid mutations in the amino acid sequence corresponding to the wild type aspartase shown in SEQ ID NO: 5, wherein the amino acid mutation is selected from the group consisting of threonine (T) at position 204, methionine (M) at position 338, Lysine (K) at position 341, asparagine (N) at position 343, or a combination thereof.

5. The method of claim 1 , wherein the aspartase has the amino acid sequence as shown in SEQ ID NO: 3.

6. The method of claim 4 , wherein the aspartase has the amino acid sequence as shown in SEQ ID NO: 3.

Assignments (2)
CHANGE OF NAME Recorded Jan 2, 2024
From: ABIOCHEM BIOTECHNOLOGY CO., LTD.
To: ABIOCHEM BIOTECHNOLOGY (GROUP) CO., LTD.
Reel/Frame 066162/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: SUN, CHUANMIN; CHENG, ZHANBING; JIAO, JIANGHUA; DING, SHAONAN; TIAN, ZHENHUA
To: ABIOCHEM BIOTECHNOLOGY CO., LTD.
Reel/Frame 052264/0963 →
Priority Claims (1)
CN 201710906645.5 · Sep 29, 2017 · national
Continuity (1)
Related Publication 20200232002A1 · Jul 23, 2020